Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.00M | 1.00M | 0.00 | 121.37M | 0.00 | 0.00 |
Gross Profit | 914.00K | 826.00K | -189.00K | 63.77M | -55.00K | -63.00K |
EBITDA | -15.34M | -22.23M | -25.52M | -115.20M | -29.15M | -19.08M |
Net Income | -19.31M | -19.98M | -20.84M | -54.23M | -27.47M | -8.15M |
Balance Sheet | ||||||
Total Assets | 28.98M | 35.00M | 54.69M | 73.03M | 97.01M | 36.00M |
Cash, Cash Equivalents and Short-Term Investments | 25.83M | 31.25M | 50.53M | 69.23M | 94.97M | 34.57M |
Total Debt | 0.00 | 137.00K | 305.00K | 485.00K | 714.00K | 624.00K |
Total Liabilities | 3.88M | 5.68M | 6.80M | 6.71M | 5.01M | 3.76M |
Stockholders Equity | 25.36M | 29.57M | 48.15M | 66.58M | 92.25M | 32.50M |
Cash Flow | ||||||
Free Cash Flow | -17.76M | -19.36M | -20.03M | -21.45M | -22.30M | -8.84M |
Operating Cash Flow | -17.73M | -19.36M | -20.03M | -21.17M | -22.25M | -8.82M |
Investing Cash Flow | 16.23M | 13.23M | 10.10M | 28.91M | -54.90M | -7.28M |
Financing Cash Flow | -87.00K | -206.00K | 385.00K | -224.00K | 85.28M | 18.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $59.95M | ― | -121.65% | ― | -0.71% | -169.29% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
43 Neutral | $22.53M | ― | -56.49% | ― | ― | 7.07% | |
38 Underperform | $14.13M | ― | -19.56% | ― | ― | 98.61% | |
35 Underperform | $21.97M | ― | -246.21% | ― | ― | 44.38% | |
33 Underperform | $22.98M | ― | -78.32% | ― | ― | 47.73% | |
$54.62M | ― | ― | ― | ― |
On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.